FDA Approves Bixlenvo, a Daily HIV Pill for Suppressed Adults
In short: On August 27, 2026, the FDA approved Bixlenvo, a once-daily tablet that combines bictegravir and lenacapavir, for adults whose HIV is already suppressed on other medicines. It manages HIV and is not a cure. The details below come from the maker, Gilead Sciences, and the FDA prescribing information.
What was approved
Gilead Sciences announced that the U.S. Food and Drug Administration approved Bixlenvo on August 27, 2026. It is a single tablet taken once a day that contains two drugs: bictegravir (75 mg) and lenacapavir (50 mg).
Bixlenvo treats HIV-1 infection. It controls the virus in the body, but it does not remove HIV, so it is not a cure.
Who it is for
The approval covers adults whose HIV is already suppressed, meaning the amount of virus in the blood is below 50 copies per milliliter. Bixlenvo is meant to replace the regimen a person is currently taking. It is not approved as a first treatment for someone newly diagnosed.
Gilead says the approval includes people on complex regimens and people with certain pre-existing drug resistance.
What the trials showed
Gilead reports that two Phase 3 trials, ARTISTRY-1 and ARTISTRY-2, showed comparable efficacy in keeping the virus suppressed at Week 48. In plain terms, people who switched did about as well as people who stayed on their previous medicines. The results were not described as better.
Gilead says the results were published in The Lancet and Lancet HIV. In ARTISTRY-1, the median age of participants was 60 years, and 67% had resistance to a class of HIV drugs called NRTIs. The summary we read comes from the company announcement, so the full trial papers are the place to check the details.
Safety information
- The most common side effects listed were headache (4%), nausea (3%) and diarrhea (2%).
- Bixlenvo must not be taken with dofetilide or with strong CYP3A inducers, which are medicines that can lower its levels.
- The label advises checking for drug interactions before and during treatment. Anyone taking HIV medicine should talk with their own clinician before changing anything.
Where it fits
Bixlenvo adds another option to the existing set of daily HIV pills for people who are already doing well on treatment. Other approaches are still in testing, including a once-weekly pill that has Phase 3 results but is not approved. Researchers are still working on a cure for HIV, and none exists today.
Frequently asked questions
Is Bixlenvo a cure for HIV?
No. Bixlenvo manages HIV by keeping the virus suppressed while it is taken. There is no cure for HIV today.
Who can take Bixlenvo?
It is approved for adults whose HIV is already suppressed (fewer than 50 copies per milliliter) on another regimen, as a replacement for that regimen. Whether it suits a particular person is a decision for them and their HIV clinician.
Is Bixlenvo better than other HIV pills?
The company reports comparable results to the regimens people were already taking at 48 weeks, not better ones. Its main value is as another switch option, and the data come from the company's announcement.
Read the full HIV report: latest studies, treatments, trials near you, expert care centers and support groups, updated daily.
Sources
- U.S. FDA approves Gilead's Bixlenvo, a new once-daily single-tablet option for virologically suppressed adults with HIV, including those on complex regimens. Gilead Sciences (company announcement), August 27, 2026
More from the newsroom
- Alzheimer's: Largest Gene Study Finds 48 New Risk Regions (October 30, 2026)
- Cystic Fibrosis: Home Monitoring Trial Misses Main Goal (October 30, 2026)
- Crohn's Disease: Skyrizi Injected Starter Doses in AFFIRM Phase 3 (October 23, 2026)